6 Jun 2014 15:00
For Immediate Release 6 June 2014
Sphere Medical Holding plc
Grant of Options
Cambridge, UK, 6 June 2014: Sphere Medical Holding plc (AIM: SPHR.L) ("Sphere Medical" or the "Company"), a leading developer of innovative monitoring and diagnostic products for the critical care setting, has today granted share options as follows:
Director No. of share options Exercise price
Dr. Wolfgang Rencken, CEO 1,320,000 (note 1) 40 pence
Matthew Hall, CFO 275,000 (note 2) 40 pence
Notes
1. Wolfgang Rencken - 625,000 share options were issued under the Company's Enterprise Management Incentive Scheme and 695,000 share options were issued under the Company's Unapproved Share Option Scheme.
2. Matthew Hall - 275,000 share options were issued under the Company's Enterprise Management Incentive Scheme.
All share options referred to are exercisable over ordinary shares of 1 pence each in the share capital of the Company ("Ordinary Shares").
These share options are subject to vesting conditions, a minimum holding period of five years from grant and have been issued at a premium of 48.1% to the 27 pence per Ordinary Share being the closing mid-market price for the Ordinary Shares on5 June 2014. The issue of these share options has been approved by the Company's Remuneration Committee.
For further information, please contact:
Sphere Medical Holding plc | Tel: +44 (0)1223 875 222 |
Dr. Wolfgang Rencken, Chief Executive Officer | |
Matthew Hall, Chief Financial Officer | |
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel | |
Clare Terlouw | |
Jock Maxwell Macdonald | |
finnCap | Tel: +44 (0) 20 7220 0500 |
Geoff Nash / Simon Hicks | |
Stephen Norcross | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5708 |
Mary-Jane Elliott | spheremedical@consilium-comms.com |
Amber Bielecka | |
Matthew Neal | |
Ivar Milligan |
Notes for Editors
Sphere Medical (AIM: SPHR.L), is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.
Sphere Medical's products deliver real time analysis of blood gases, electrolytes and drug levels with laboratory accuracy, at the patient's bedside. Sphere Medical's products can be used in a wide range of medical applications, enabling faster clinical decision making and improved patient outcomes, whilst reducing costs for healthcare payers.
Sphere Medical has entered into a collaboration agreement entered with Ortho-Clinical Diagnostics, Inc. for the development of Proxima and enhancement of Sphere's operational and production capabilities.
Sphere Medical has a number of partnerships with industry leading medical device companies and has received a strategic investment from Johnson & Johnson Development Corporation.
For further information, please visit www.spheremedical.com